أنشئ حسابًا أو سجّل الدخول للانضمام إلى مجتمعك المهني.
neoadjuvant chemotherapy is effective against triple negative breast cancer, neoadjuvant chemotherapy is “administration of a chemotherapic drug and then surgery”. It enhance overall and disease free survival. The inhibitors of PARP, such as Lynparza (chemical name: olaparib) and Talzenna (chemical name: talazoparib), have been approved to treat advanced-stage HER2-negative breast cancer in people with a BRCA1 or BRCA2 mutation. The immunotherapy medicine Keytruda (chemical name: pembrolizumab) is used to treat triple-negative breast cancer. Keytruda is used in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Reference
BreastCancer.org
